Peran Mycophenolate Sodium pada Nefritis Lupus

Oleh :

dr.Restie Warapsari, Sp.PD

Mycophenolate sodium (MPS) merupakan preparate mycophenolic acid (MPA) yang digunakan untuk pengobatan nefritis lupus (NL). MPS memiliki toksisitas pada saluran gastrointestinal yang lebih rendah daripada mycophenolate mofetil (MMF).[1]

Mycophenolate mofetil adalah pro-drug dari mycophenolic acid (MPA) yang memiliki margin terapeutik lebih luas dan efek samping lebih ringan dibanding siklofosfamid (CYC). MMF dilaporkan tidak lebih inferior dibanding CYC untuk terapi fase induksi, dan lebih superior dari azathioprine (AZA) untuk terapi fase rumatan.[2]

Namun, pengobatan MMF dipersulit dengan efek samping mual, muntah, diare, dan nyeri perut. Sehingga saat ini, dikembangkan Mycophenolate sodium (MPS) yang dapat mengurangi toksisitas pada saluran gastrointestinal ini.[3]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Zhang W, Ding C, Zheng S. Enteric-coated mycophenolate sodium: an update. Int J Clin Pract Suppl. 2014; (181):1-3.
2. Mok CC. Mycophenolate Mofetil for Lupus Nephritis: an update. Expert Rev Clin Immunol. 2015; :1353-64
3. Liao YW, Hung WT, Chen MY, et al. Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis. J Clin Rheumatol. 2022; 28(2): e633-e637
4. Mok CC, Cheung MY, Ho LY, et al. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus. 2008; 17:1103-7
5. Subramanian R, Pathak H, Ravindran V. Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases. Indian Journal of Rheumatology. 2019;14(2):127-135.
6. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64:797–808
7. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nphritis: Core Curriculum 2020. Am J Kidney Dis. 2020;76(2):265-281
8. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanis MPS of action. Immunopharmacology. 2000; 47:85-118
9. FDA. Myfortic® (mycophenolic acid*) delayed-release tablets *as mycophenolate sodium.2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050791s011lbl.pd
10. Langone AJ, Chan L, Bolin P, et al. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multi-center, double-blind, randomized study. Transplantation. 2011; 91: 470–478.
11. Lopez-Solis R, DeVera M, Steel J, et al. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. Mycophenolate mofetil. Clin Transplant. 2014; 28: 783–788.
12. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–1782.
13. Traitanon O, Avihingsanon Y, Kittikovit V et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus. 2008; 17(8): 744–51.
14. Appel GB, Contreras G, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol. 2009; 20(5): 1103–1112.
15. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95